The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series of AGC kinases, is universally active in MM, and plays pivotal roles in cell proliferation and cell survival of myeloma cells regardless of the profiles of cytogenetic and genetic abnormalities. This study investigated the therapeutic efficacy and mechanism of action of dual blockade of two major PDPK1 substrates, RSK2 and AKT, in MM. The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation. Moreover, the dual blockade of RSK2 and AKT exerted robust molecular effects on critical gene sets associated with myeloma pathophysiologies, such as those with MYC, mTOR, STK33, ribosomal biogenesis, or cell-extrinsic stimuli of soluble factors, in HMCLs. These results provide the biological and molecular rationales for the dual-targeting strategy for RSK2 and AKT, which may overcome the therapeutic difficulty due to cytogenetic/molecular heterogeneity in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The PI3K/AKT/mTOR signaling pathway plays a crucial role in MM pathogenesis by regulating various cellular processes such as proliferation, migration, apoptosis, and autophagy.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This pathway is frequently activated in MM due to oncogenic events and extrinsic stimulation [65].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“org, accessed on 1 December 2021) [32,67].”
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“DRI = 1 indicates no dose reduction, whereas DRI > 1 and <1 indicate favorable and unfavorable dose-reduction, respectively [66].”
BackgroundHeterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Multiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765 · cited 1×
“Multiple myeloma (MM) is a clonal plasma cell neoplasm, and is the second most common hematologic malignancy [1].”
BackgroundIRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood · doi:10.1182/blood-2018-03-840132 · Cited by 475
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Regulation and function of the RSK family of protein kinases
Romeo, Y., Zhang, X., & Roux, P. P. (2012) · Biochemical Journal · doi:10.1042/bj20110289 · Cited by 377 · cited 1×
“of RAS/RAF/ERK pathway [39,40], the therapeutic effect of single targeting of RAS or RAF might be hampered by the PDPK1-mediated constitutive active status of RSK2, which is independent of RAS/RAF/ERK activity in myeloma cells, while the blockade of AKT alone has only cytostatic effects but no major cell killing effec…”
BackgroundCragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 343
Self-citationBI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
Sapkota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M., et al. (2007) · Biochemical Journal · doi:10.1042/bj20061088 · Cited by 308 · cited 1×
“The agents used were BI-D1870, which selectively inhibits the phosphorylation of RSK2Ser227 at NTKD in an ATP-competitive manner [64] (Cayman Chemical Company, Ann Arbor, MI, USA), and ipatasertib, which binds to AKT in an ATP-competitive manner and prevents substrate phosphorylation [65] (Selleck Biotech Ltd.”
MethodKortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255 · cited 10×
“Given that the inhibition of mTORC2 has the synergistic anti-MM effects with a proteasome inhibitor and IMiD [51,52], the dual blockade of RSK2 and AKT may be expected to enhance the effects of proteasome inhibitors and IMiDs on myeloma cells.”
BackgroundInfluentialThe RSK factors of activating the Ras/MAPK signaling cascade
Carriere, A. (2008) · Frontiers in Bioscience · doi:10.2741/3003 · Cited by 217
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 206 · cited 1×
“MYC is a multifunctional oncogenic transcription factor that affects various cell biological processes, including cell proliferation, apoptosis, and DNA damage in various cancerous diseases, including myeloma [44,45].”
BackgroundBlake, J. F., Xu, R., Bencsik, J. R., Xiao, D., Kallan, N. C., Schlachter, S., Mitchell, I. S., Spencer, K. L., Banka, A. L., Wallace, E. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301024w · Cited by 191 · cited 1×
“The agents used were BI-D1870, which selectively inhibits the phosphorylation of RSK2Ser227 at NTKD in an ATP-competitive manner [64] (Cayman Chemical Company, Ann Arbor, MI, USA), and ipatasertib, which binds to AKT in an ATP-competitive manner and prevents substrate phosphorylation [65] (Selleck Biotech Ltd.”
MethodLopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08689.x · Cited by 181 · cited 1×
“The therapeutic efficacy of IMiDs, such as lenalidomide and pomalidomide, has been known to be partly mediated by the repression of MYC through the blockade of IKZF family proteins and ARID2 [49,50].”
BackgroundLessard, F., Igelmann, S., Trahan, C., Huot, G., Saint-Germain, E., Mignacca, L., Del Toro, N., Lopes-Paciencia, S., Le Calvé, B., Montero, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0127-y · Cited by 174 · cited 1×
“Although the pathologic role of abnormal expression of RSP14 has not been known in MM, the blockade of RSP14 has been shown to exhibit a tumor-suppressive role regardless of TP53 status in solid and hematologic cancers [55].”
BackgroundCell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
Targeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 142 · cited 1×
“MYC is a multifunctional oncogenic transcription factor that affects various cell biological processes, including cell proliferation, apoptosis, and DNA damage in various cancerous diseases, including myeloma [44,45].”
BackgroundCo-evolution of tumor and immune cells during progression of multiple myeloma
Liu, R., Gao, Q., Foltz, S. M., Fowles, J. S., Yao, L., Wang, J. T., Cao, S., Sun, H., Wendl, M. C., Sethuraman, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22804-x · Cited by 133
Thorsteinsdottir, S., Dickman, P. W., Landgren, O., Blimark, C., Hultcrantz, M., Turesson, I., Björkholm, M., & Kristinsson, S. Y. (2018) · Haematologica · doi:10.3324/haematol.2017.183475 · Cited by 131
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells
van Nieuwenhuijzen, N., Spaan, I., Raymakers, R. A. P., & Peperzak, V. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3115 · Cited by 129
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
Binder, M., Nandakumar, B. N., Rajkumar, S. V., Kapoor, P., Buadi, F. K., Dingli, D., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Leung, N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01453-5 · Cited by 111
Nagoshi, H., Taki, T., Hanamura, I., Nitta, M., Otsuki, T., Nishida, K., Okuda, K., Sakamoto, N., Kobayashi, S., Yamamoto-Sugitani, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0213 · Cited by 101
Self-citationARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 98 · cited 2×
“The therapeutic efficacy of IMiDs, such as lenalidomide and pomalidomide, has been known to be partly mediated by the repression of MYC through the blockade of IKZF family proteins and ARID2 [49,50].”
BackgroundCaspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes
Ferreira, K. S., Kreutz, C., MacNelly, S., Neubert, K., Haber, A., Bogyo, M. S., Timmer, J., & Borner, C. (2012) · APOPTOSIS · doi:10.1007/s10495-011-0691-0 · Cited by 91 · cited 1×
“We hypothesize that Caspase-3 may be involved in Caspase-8 feedback activity to promote proteolytic processing [43].”
BackgroundPI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Ramakrishnan, V., & Kumar, S. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1421760 · Cited by 89
Giannakoulas, N., Ntanasis-Stathopoulos, I., & Terpos, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094462 · Cited by 87
Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M., & Bargou, R. C. (2011) · Blood · doi:10.1182/blood-2010-05-284422 · Cited by 81
Ziccheddu, B., Biancon, G., Bagnoli, F., De Philippis, C., Maura, F., Rustad, E. H., Dugo, M., Devecchi, A., De Cecco, L., Sensi, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000779 · Cited by 78
Shirazi, F., Jones, R. J., Singh, R. K., Zou, J., Kuiatse, I., Berkova, Z., Wang, H., Lee, H. C., Hong, S., Dick, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005052117 · Cited by 75
Immune-based therapies in the management of multiple myeloma
Zanwar, S., Nandakumar, B. N., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00350-x · Cited by 68 · cited 1×
“Thanks to major players including proteasome inhibitors (PIs), immune therapeutics immunomodulatory drugs (IMiDs), and monoclonal antibodies (MoAbs) against CD38 or SLAMF-7, the treatment outcome of MM has been greatly improved [25,26]; however, the disease is still mostly incurable even with the latest cellular immun…”
BackgroundMikulášová, A., Ashby, C., Tytarenko, R. G., Qu, P., Rosenthal, A., Dent, J. A., Ryan, K. R., Bauer, M., Wardell, C. P., Hoering, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.217927 · Cited by 67
Immunopathogenesis and immunotherapy of multiple myeloma
Tamura, H. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2405-7 · Cited by 64
BCMA in Multiple Myeloma—A Promising Key to Therapy
Kleber, M., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184088 · Cited by 64 · cited 1×
“Thanks to major players including proteasome inhibitors (PIs), immune therapeutics immunomodulatory drugs (IMiDs), and monoclonal antibodies (MoAbs) against CD38 or SLAMF-7, the treatment outcome of MM has been greatly improved [25,26]; however, the disease is still mostly incurable even with the latest cellular immun…”
BackgroundSolimando, A. G., Vià, M. D., Leone, P., Borrelli, P., Croci, G. A., Tabares, P., Brandl, A., Lernia, G. D., Bianchi, F. P., Tafuri, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.239913 · Cited by 63
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
Lamanuzzi, A., Saltarella, I., Desantis, V., Frassanito, M. A., Leone, P., Racanelli, V., Nico, B., Ribatti, D., Ditonno, P., Prete, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25003 · Cited by 60 · cited 9×
“Given that the inhibition of mTORC2 has the synergistic anti-MM effects with a proteasome inhibitor and IMiD [51,52], the dual blockade of RSK2 and AKT may be expected to enhance the effects of proteasome inhibitors and IMiDs on myeloma cells.”
BackgroundInfluentialMolecular basis of clonal evolution in multiple myeloma
Furukawa, Y., & Kikuchi, J. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02829-6 · Cited by 60
Shibata, T., Watari, K., Kawahara, A., Sudo, T., Hattori, S., Murakami, Y., Izumi, H., Itou, J., Toi, M., Akiba, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0690 · Cited by 59 · cited 1×
“To implement this strategy in a clinical environment, the clinical development of bioavailable dual inhibitors for RSK2 and AKT is expected for MM [63].”
BackgroundPeng, C., Cho, Y., Zhu, F., Zhang, J., Wen, W., Xu, Y., Yao, K., Ma, W.-Y., Bode, A. M., & Dong, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172338 · Cited by 57 · cited 1×
“In addition, BI-D1870 treatment caused the processing of Caspase-8 to its cleaved form in HMCLs, which was consistent with a previous report showing that the blockade of RSK2 abrogates Caspase-8 stability [42].”
ResultMutational processes contributing to the development of multiple myeloma
Hoang, P. H., Cornish, A. J., Dobbins, S. E., Kaiser, M., & Houlston, R. S. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0221-9 · Cited by 53
Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways
Dehghanifard, A., Kaviani, S., Abroun, S., Mehdizadeh, M., Saiedi, S., Maali, A., Ghaffari, S., & Azad, M. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.03.007 · Cited by 52
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
Botta, C., Mendicino, F., Martino, E. A., Vigna, E., Ronchetti, D., Correale, P., Morabito, F., Neri, A., & Gentile, M. (2021) · Cancers · doi:10.3390/cancers13133213 · Cited by 52
STK33 promotes hepatocellular carcinoma through binding to c-Myc
Yang, T., Song, B., Zhang, J., Yang, G.-S., Zhang, H., Yu, W., Wu, M., Lu, J., & Shen, F. (2014) · Gut · doi:10.1136/gutjnl-2014-307545 · Cited by 47 · cited 1×
“STK33 has been known to participate in the transcriptional activation of c-MYC [56], and also contributes to the angiogenetic process as the mediator of hypoxia-inducible factor-1α/VEGF signaling [57].”
BackgroundKuwahara‐Ota, S., Shimura, Y., Steinebach, C., Isa, R., Yamaguchi, J., Nishiyama, D., Fujibayashi, Y., Takimoto‐Shimomura, T., Mizuno, Y., Matsumura‐Kimoto, Y., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16881 · Cited by 45 · cited 3×
“WB analysis was performed as previously stated (Supplementary Information) [5,23, 29,30,32,33].”
MethodSelf-citationDeficient Spindle Assembly Checkpoint in Multiple Myeloma
Díaz-Rodríguez, E., Álvarez-Fernández, S., Chen, X., Paiva, B., López‐Pérez, R., García, J. L., Miguel, J. F. S., & Pandiella, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027583 · Cited by 41
Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma
Chinen, Y., Kuroda, J., Shimura, Y., Nagoshi, H., Kiyota, M., Yamamoto-Sugitani, M., Mizutani, S., Sakamoto, N., Ri, M., Kawata, E., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1420 · Cited by 36 · cited 6×
“The antibodies used are also described in Supplementary Information.”
BackgroundMethodInfluentialSelf-citationAwada, H., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., & Dhakal, B. (2021) · Cells · doi:10.3390/cells10081961 · Cited by 35
Pathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 34 · cited 1×
“However, the clinical development of pathway-directed therapeutics targeting either RAS, RAF, PI3K, or AKT as the single target has failed in yielding results until today [37,38].”
BackgroundFujibayashi, Y., Isa, R., Nishiyama, D., Sakamoto-Inada, N., Kawasumi, N., Yamaguchi, J., Kuwahara‐Ota, S., Matsumura‐Kimoto, Y., Tsukamoto, T., Chinen, Y., et al. (2020) · Cancers · doi:10.3390/cancers12082206 · Cited by 33 · cited 4×
“WB analysis was performed as previously stated (Supplementary Information) [5,23, 29,30,32,33].”
MethodInfluentialSelf-citationAcute regulation of PDK1 by a complex interplay of molecular switches
Calleja, V., Laguerre, M. S., Heras‐Martínez, G. D. L., Parker, P. J., Requejo‐Isidro, J., & Larijani, B. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140222 · Cited by 32 · cited 1×
“However, giving PDPK1 broad function as the master regulator of at least 23 AGC kinases, such as RSKs, p70S6K, AKT, PKC, and ILK, as well as the regulator of various non-AGC kinases, such as PLK-1, β3integrin, or ROCK1, therapeutic inhibition of PDPK1 could result in a variety of unwanted off-target effects [31].”
BackgroundRSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Shimura, Y., Kuroda, J., Ri, M., Nagoshi, H., Yamamoto‐Sugitani, M., Kobayashi, T., Kiyota, M., Nakayama, R., Mizutani, S., Chinen, Y., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0605 · Cited by 32
Self-citationEichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 32
Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
Saltarella, I., Lamanuzzi, A., Apollonio, B., Desantis, V., Bartoli, G., Vacca, A., & Frassanito, M. A. (2021) · Cells · doi:10.3390/cells10113185 · Cited by 32
Emerging protein kinase inhibitors for the treatment of multiple myeloma
Lind, J., Czernilofsky, F., Vallet, S., & Podar, K. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1647165 · Cited by 27 · cited 1×
“However, the clinical development of pathway-directed therapeutics targeting either RAS, RAF, PI3K, or AKT as the single target has failed in yielding results until today [37,38].”
BackgroundTatekawa, S., Chinen, Y., Ri, M., Narita, T., Shimura, Y., Matsumura‐Kimoto, Y., Tsukamoto, T., Kobayashi, T., Kawata, E., Uoshima, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14707 · Cited by 26 · cited 4×
“WB analysis was performed as previously stated (Supplementary Information) [5,23, 29,30,32,33].”
BackgroundMethodInfluentialSelf-citationLiu, Y., Steinestel, K., ROUHI, A. M., Armacki, M., Diepold, K., Chiosis, G., Simmet, T., Seufferlein, T. T. W., & Azoitei, N. (2017) · Oncotarget · doi:10.18632/oncotarget.20535 · Cited by 26 · cited 1×
“STK33 has been known to participate in the transcriptional activation of c-MYC [56], and also contributes to the angiogenetic process as the mediator of hypoxia-inducible factor-1α/VEGF signaling [57].”
BackgroundYu, W., Chen, Y., Xiang, R., Xu, W., Wang, Y., Tong, J., Zhang, N., Wu, Y., & Yan, H. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1190968 · Cited by 24 · cited 1×
“Mechanistically, oncogenic activation of RAS/RAF/ERK signaling is one of the mechanisms that enhance proteasome capacity, while treatment with PI causes the phosphorylation of AKT [59,60], and both mechanisms contribute to the resistance to proteasome inhibition in myeloma cells.”
BackgroundQiu, Q., Jiang, J., Lin, L., Cheng, S., Xin, D., Jiang, W., Shen, J., & Hu, Z. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3481 · Cited by 22
Akt regulates RSK2 to alter phosphorylation level of H2A.X in breast cancer
Guo, Z., & Kong, F.-L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12448 · Cited by 22
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
Hoang, P. H., Cornish, A. J., Sherborne, A. L., Chubb, D., Kimber, S. T., Jackson, G. H., Morgan, G. J., Cook, G., Kinnersley, B., Kaiser, M., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00367-2 · Cited by 20
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Walker, Z. J., Idler, B. M., Davis, L. N., Stevens, B. M., VanWyngarden, M. J., Ohlstrom, D. J., Bearrows, S. C., Hammes, A., Smith, C. A., Jordan, C. T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2246 · Cited by 19 · cited 1×
“Moreover, the resistant mechanisms for current standard therapeutics for MM include aberrant MYC overexpression [50], and the increased rate of protein translation [62].”
BackgroundEverolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway
Li, J., Liu, Z., Li, Y., Jing, Q., Wang, H., Liu, H., Chen, J., Feng, J., Shao, Q., & Fu, R. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000780 · Cited by 15 · cited 9×
“Given that the inhibition of mTORC2 has the synergistic anti-MM effects with a proteasome inhibitor and IMiD [51,52], the dual blockade of RSK2 and AKT may be expected to enhance the effects of proteasome inhibitors and IMiDs on myeloma cells.”
BackgroundInfluentialKinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8501 · Cited by 14 · cited 9×
“Given that the inhibition of mTORC2 has the synergistic anti-MM effects with a proteasome inhibitor and IMiD [51,52], the dual blockade of RSK2 and AKT may be expected to enhance the effects of proteasome inhibitors and IMiDs on myeloma cells.”
BackgroundInfluentialMatsumura‐Kimoto, Y., Tsukamoto, T., Shimura, Y., Chinen, Y., Tanba, K., Kuwahara‐Ota, S., Fujibayashi, Y., Nishiyama, D., Isa, R., Yamaguchi, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3136 · Cited by 13 · cited 3×
“WB analysis was performed as previously stated (Supplementary Information) [5,23, 29,30,32,33].”
MethodSelf-citationGenetic variants as biomarkers for progression and resistance in multiple myeloma
Montel, R. A., Gregory, M., Chu, T.-C., Cottrell, J. A., Bitasktsis, C., & Chang, S. L. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.12.001 · Cited by 8
The clonal evolution during long-term clinical course of multiple myeloma
Mishima, Y. M., Mishima, Y., Shirouchi, Y., Nishimura, N., Yokoyama, M., Okabe, T., Inoue, N., Uryu, H., Fukuta, T., Hatake, K., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02979-7 · Cited by 4
Cited by
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Hu, S., Xu, J., Cui, W., Jin, H.-R., Wang, X., & Maimaitiyiming, Y. (2025) · Biomolecules · doi:10.3390/biom15050702 · Cited by 11
“INPP4B enhances the efficacy of bortezomib by suppressing phosphorylation of Akt at Ser473, thereby attenuating PI3K/Akt/mTOR pathway activity, whereas loss of INPP4B leads to Akt hyperactivation and drug resistance [120–122].”
Doi, T., Takahashi, S., Aoki, D., Yonemori, K., Hara, H., Hasegawa, K., Takehara, K., Harano, K., Yunokawa, M., Nomura, H., et al. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04631-7 · Cited by 9
Karathanasis, N., & Spyrou, G. M. (2025) · Cancers · doi:10.3390/cancers17020332 · Cited by 10
“For instance, the PI3K-Akt pathway has been widely recognized as a key player in MM, influencing proliferation, migration, apoptosis, and autophagy [43].”
Katsuragawa‐Taminishi, Y., Mizutani, S., Kawaji‐Kanayama, Y., Onishi, A., Okamoto, H., Isa, R., Mizuhara, K., Muramatsu, A., Fujino, T., Tsukamoto, T., et al. (2023) · Cancer Science · doi:10.1111/cas.15995 · Cited by 6
“10,11 14 Importantly, the PDPK1/RSK2 signaling axis is universally active in MCL and MM, and the blockade of this pathway has antitumor effects, regardless of cytogenetic/molecular manifestations in MM. 10–14 These evoke the idea of further investigating the values of PDPK1 and its effector…”
BackgroundSelf-citation
Metadata
- Authors
- Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., Mizutani, S., Shimura, Y., Taniwaki, M., Sakai, T., & Kuroda, J.
- Affiliations
- Kyoto Prefectural University of Medicine (JP)
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
- Corresponding author
- Kuroda, Junya
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-08
- Volume
- 23
- Issue
- 6
- Pages
- 2919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8949999
- OpenAlex
- W4220992956
- Semantic Scholar
- 1f38141255b372f5b40f14a121ef47766edbf526
- Cited by
- 11
- References
- 67
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (19K08872)
- The Japanese Society Hematology Research Grant (N.A.)
- The Japan Leukemia Research Fund Award (N.A.)
- Japan Agency for Medical Research and Development (JP19ck0106516h0001)
- Japanese Society for Myeloma Research Award (N.A.)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, RSK2, Akt, PDPK1, dual-targeted therapy, BI-D1870, ipatasertib, AGC kinases, apoptosis, building information modeling, Bid, c-Myc, mTOR, STK33, ribosome biogenesis, cytogenetic heterogeneity, combination therapy
- MeSH terms
- Humans, Multiple Myeloma, Protein Serine-Threonine Kinases, Ribosomal Protein S6 Kinases, 90-kDa, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, 3-Phosphoinositide-Dependent Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.